
Belantamab Mafodotin in Daratumumab-Exposed Relapsed/Refractory Multiple Myeloma
Dr. Joshua Richter and Dr. Surbhi Sidana discuss the applicability of DREAMM-7 findings to patients with relapsed/refractory multiple myeloma who have received prior daratumumab-based frontline therapy.
Episodes in this series
Dr. Joshua Richter and Dr. Surbhi Sidana discuss the applicability of DREAMM-7 findings to patients with relapsed/refractory multiple myeloma who have received prior daratumumab-based frontline therapy. They consider how daratumumab exposure and refractoriness may influence outcomes with subsequent treatment, noting that DREAMM-7 excluded patients who were daratumumab-refractory or refractory or intolerant to bortezomib. Dr. Sidana discusses the potential role of belantamab mafodotin-based combinations in this setting, particularly for patients who are daratumumab-refractory and may have limited options for daratumumab-containing regimens. Dr. Richter highlights the rationale for considering BCMA-directed therapies earlier in the treatment sequence and discusses the potential role of antibody-drug conjugates alongside CAR T-cell therapies and bispecific antibodies. The experts also explore treatment considerations for older or frailer patients, including the potential value of less frequent, lower-dose belantamab mafodotin approaches while balancing efficacy, toxicity, and patient preferences.
Related to this article








